EU Framework Programme (Horizon 2020) for Acceleration of New Inhaled Medicines

LANCASTER, Calif.– Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of modeling and simulation software for pharmaceutical discovery and development, today announced that it has been accepted into the SimInhale COST (European Cooperation in Science and Technology) Action, a consortium composed of approximately 100 current university, research institute, and industry members from across Europe.

As one of only two U.S. participants, Simulations Plus will participate in activities designed to:

advance particle designs for improved deposition and interaction with lung tissue

promote realistic computer simulations of particle aerosolization, delivery and deposition

promote patient-tailored inhaled medicines

promote integration of device and formulation design

promote critical assessment of toxicity issues and related risks

SimInhale will establish a roadmap to rea